Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOVF Swedish Orphan Biovitrum	$28.97	$29.57	$25.80 ▼ $32.25	$10.31B	0.46	39 shs	N/A
BMRN BioMarin Pharmaceutical	$58.07 +0.2%	$57.43	$52.93 ▼ $93.04	$11.15B	0.18	1.94 million shs	1.41 million shs
BVNRY Bavarian Nordic	$12.31 -0.4%	$10.38	$6.60 ▼ $14.11	$2.91B	1.36	7,903 shs	12,166 shs
QGEN QIAGEN	$49.13 -0.1%	$48.53	$37.63 ▼ $51.88	$10.92B	0.64	1.37 million shs	695,538 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOVF Swedish Orphan Biovitrum	0.00%	0.00%	-2.75%	-5.02%	+20.33%
BMRN BioMarin Pharmaceutical	+1.13%	-0.58%	+2.48%	-0.09%	-38.24%
BVNRY Bavarian Nordic	+0.98%	-0.96%	+28.38%	+45.29%	-2.29%
QGEN QIAGEN	+0.13%	-0.06%	+2.42%	+16.30%	+7.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIOVF Swedish Orphan Biovitrum	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	4.9964 of 5 stars	4.4	5.0	0.0	3.3	3.0	1.7	4.4
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QGEN QIAGEN	3.7612 of 5 stars	1.1	2.0	1.7	4.5	3.4	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIOVF Swedish Orphan Biovitrum	4.00	Strong Buy	N/A	N/A
BMRN BioMarin Pharmaceutical	2.72	Moderate Buy	$93.17	60.45% Upside
BVNRY Bavarian Nordic	0.00	N/A	N/A	N/A
QGEN QIAGEN	2.27	Hold	$49.69	1.12% Upside

Current Analyst Ratings Breakdown

Latest BVNRY, BMRN, QGEN, and BIOVF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	BMRN BioMarin Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/7/2025	QGEN QIAGEN	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/7/2025	QGEN QIAGEN	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$48.00 ➝ $50.00
8/6/2025	BMRN BioMarin Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$101.00 ➝ $106.00
8/5/2025	BMRN BioMarin Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$94.00
8/5/2025	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$113.00 ➝ $114.00
7/22/2025	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$97.00 ➝ $96.00
7/15/2025	BMRN BioMarin Pharmaceutical	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$95.00
7/14/2025	BMRN BioMarin Pharmaceutical	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$108.00 ➝ $113.00
7/3/2025	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$97.00
6/26/2025	QGEN QIAGEN	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $53.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIOVF Swedish Orphan Biovitrum	$2.46B	4.19	$2.05 per share	14.12	$11.36 per share	2.55
BMRN BioMarin Pharmaceutical	$2.85B	3.91	$3.29 per share	17.66	$31.39 per share	1.85
BVNRY Bavarian Nordic	$829.12M	3.51	$1.02 per share	12.08	$6.99 per share	1.76
QGEN QIAGEN	$1.98B	5.52	$3.20 per share	15.35	$15.77 per share	3.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIOVF Swedish Orphan Biovitrum	$367.52M	$1.19	24.34	∞	N/A	16.05%	11.67%	6.34%	10/23/2025 (Estimated)
BMRN BioMarin Pharmaceutical	$426.86M	$3.37	17.23	13.32	0.74	21.45%	12.59%	10.13%	11/4/2025 (Estimated)
BVNRY Bavarian Nordic	$143.26M	$0.80	15.38	11.72	N/A	21.11%	11.89%	9.32%	8/28/2025 (Estimated)
QGEN QIAGEN	$83.59M	$1.69	29.03	19.97	2.58	18.30%	14.77%	8.87%	11/5/2025 (Estimated)

Latest BVNRY, BMRN, QGEN, and BIOVF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2025	Q2 2025	QGEN QIAGEN	$0.60	$0.60	N/A	$0.44	$523.97 million	$533.54 million
7/16/2025	Q2 2025	BIOVF Swedish Orphan Biovitrum	$0.18	$0.24	+$0.06	$0.19	$644.68 million	$649.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIOVF Swedish Orphan Biovitrum	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A
QGEN QIAGEN	$0.25	0.51%	N/A	14.79%	N/A

Latest BVNRY, BMRN, QGEN, and BIOVF Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/1/2025	QGEN QIAGEN		$0.25	0.52%	7/2/2025	7/3/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIOVF Swedish Orphan Biovitrum	0.22	1.00	0.66
BMRN BioMarin Pharmaceutical	0.10	5.56	3.60
BVNRY Bavarian Nordic	N/A	2.81	1.44
QGEN QIAGEN	0.25	1.61	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIOVF Swedish Orphan Biovitrum	N/A
BMRN BioMarin Pharmaceutical	98.71%
BVNRY Bavarian Nordic	N/A
QGEN QIAGEN	70.00%

Insider Ownership

Company	Insider Ownership
BIOVF Swedish Orphan Biovitrum	N/A
BMRN BioMarin Pharmaceutical	0.85%
BVNRY Bavarian Nordic	N/A
QGEN QIAGEN	9.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIOVF Swedish Orphan Biovitrum	1,937	356.00 million	N/A	Not Optionable
BMRN BioMarin Pharmaceutical	3,040	192.01 million	190.38 million	Optionable
BVNRY Bavarian Nordic	1,611	236.57 million	N/A	Not Optionable
QGEN QIAGEN	5,765	222.29 million	202.29 million	Optionable

BVNRY, BMRN, QGEN, and BIOVF Headlines

Recent News About These Companies

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis

August 21 at 10:04 AM | seekingalpha.com

Wellington Management Group LLP Increases Holdings in Qiagen N.V. $QGEN

August 21 at 5:27 AM | marketbeat.com

Russell Investments Group Ltd. Reduces Stake in QIAGEN N.V. $QGEN

August 21 at 3:59 AM | marketbeat.com

Stocks Showing Rising Market Leadership: Qiagen Earns 81 RS Rating

August 20 at 3:47 PM | msn.com

Qiagen Executive Sells Significant Shareholding

August 19 at 11:10 AM | msn.com

QIAGEN N.V. $QGEN Holdings Raised by Public Sector Pension Investment Board

August 19 at 4:45 AM | marketbeat.com

Neuberger Berman Group LLC Acquires 9,791 Shares of Qiagen N.V. (NYSE:QGEN)

August 18 at 5:12 AM | marketbeat.com

Nuveen LLC Invests $44.08 Million in Qiagen N.V. (NYSE:QGEN)

August 18 at 4:30 AM | marketbeat.com

QIAGEN N.V. Announces Managerial Share Sale by Roland Sackers

August 18 at 3:48 AM | msn.com

Sector Gamma AS Reduces Holdings in Qiagen N.V. (NYSE:QGEN)

August 17, 2025 | marketbeat.com

QIAGEN N.V. (NYSE:QGEN) Shares Acquired by Prudential PLC

August 16, 2025 | marketbeat.com

Kepler Capital Remains a Hold on Qiagen (QGEN)

August 15, 2025 | theglobeandmail.com

Citigroup Inc. Acquires 160,799 Shares of QIAGEN N.V. (NYSE:QGEN)

August 15, 2025 | marketbeat.com

US Court of Appeals Reverses Patent Infringement Verdict Against Qiagen

August 14, 2025 | 360dx.com3

Qiagen N.V. (NYSE:QGEN) Shares Purchased by Forsta AP Fonden

August 14, 2025 | marketbeat.com

Swiss National Bank Reduces Stock Holdings in QIAGEN N.V. (NYSE:QGEN)

August 14, 2025 | marketbeat.com

Nuance Investments LLC Sells 1,366,663 Shares of QIAGEN N.V. (NYSE:QGEN)

August 13, 2025 | marketbeat.com

William Blair Forecasts Qiagen's Q2 Earnings (NYSE:QGEN)

August 12, 2025 | marketbeat.com

QIAGEN (NYSE:QGEN) Downgraded by Wall Street Zen to "Buy"

August 12, 2025 | americanbankingnews.com

Why Qiagen (QGEN) International Revenue Trends Deserve Your Attention

August 11, 2025 | zacks.com

Qiagen (NYSE:QGEN) Cut to Buy at Wall Street Zen

August 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVNRY, BMRN, QGEN, and BIOVF Company Descriptions

Swedish Orphan Biovitrum OTCMKTS:BIOVF

$28.97 0.00 (0.00%)

As of 08/19/2025

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

BioMarin Pharmaceutical NASDAQ:BMRN

$58.07 +0.11 (+0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$57.74 -0.33 (-0.57%)

As of 04:58 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Bavarian Nordic OTCMKTS:BVNRY

$12.31 -0.05 (-0.36%)

As of 11:38 AM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

QIAGEN NYSE:QGEN

$49.13 -0.07 (-0.13%)

Closing price 03:59 PM Eastern

Extended Trading

$49.14 +0.00 (+0.00%)

As of 04:20 PM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time